Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines

Dermatol Surg. 2013 Jul;39(7):1088-96. doi: 10.1111/dsu.12175. Epub 2013 Mar 6.

Abstract

Background: Botulinum toxin type A (BoNT-A) injection has become the most popular cosmetic nonsurgical procedure, and it has been suggested that BoNT-A injections may improve emotional states when frown lines are treated.

Objectives: To evaluate symptoms of depression and self-esteem before and after onabotulinumtoxinA (ONA) injections in the glabella in subjects with and without depression.

Methods: Twenty-five subjects with depression were allocated into one group and 25 subjects without depression were matched to those according to demographic characteristics. The Beck Depression Inventory (BDI) and Rosenberg Self-Esteem Scale (RSES) were used to assess depression symptoms and self-esteem, respectively. Patients were assessed up to 12 weeks after the intervention.

Results: Patients with depression had significant improvement in depression symptoms after ONA injections. The maximum effect occurred within the first 8 weeks after treatment. A significant reduction from baseline in BDI score and significant improvement in self-esteem were also observed in patients with depression.

Conclusion: This research presents new data regarding BoNT-A as a potential treatment to improve depression symptoms in patients with Major Depressive Disorder. Self-esteem scores alone cannot explain the improvement in depression symptoms.

MeSH terms

  • Adult
  • Botulinum Toxins, Type A / pharmacology*
  • Botulinum Toxins, Type A / therapeutic use
  • Depressive Disorder, Major / psychology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuromuscular Agents / pharmacology*
  • Neuromuscular Agents / therapeutic use
  • Prospective Studies
  • Self Concept*
  • Skin Aging / drug effects*

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A